Find Paid Clinical Trials in Colorado

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in Colorado

Top of Directory » All Locations » United States » Colorado




  • A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne

    Condition:   Acne Vulgaris
    Interventions:   Drug: Tazarotene foam;   Drug: Vehicle Foam
    Sponsor:   Stiefel, a GSK Company
    Recruiting - verified November 2009

  • A Study of OSI-906 and Irinotecan in Patients With Advanced Cancer With Expanded Cohorts of Patients With KRAS Mutant Colorectal Cancer

    Condition:   Colorectal Cancer
    Intervention:   Drug: Treatment with OSI-906 and/or irinotecan
    Sponsor:   University of Colorado at Denver and Health Sciences Center
    Not yet recruiting - verified November 2009

  • Depression Management at the Workplace

    Condition:   Depression
    Interventions:   Other: Depression Product Detailing;   Other: Depression HEDIS detailing
    Sponsors:   Florida State University;   Colorado Business Group on Health
    Recruiting - verified November 2009

  • Lung Cancer Mutation Consortium Protocol

    Condition:   Stage IIIB/IV Adenocarcinoma
    Intervention:   Other: No intervention
    Sponsors:   University of Colorado at Denver and Health Sciences Center;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

    Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms
    Interventions:   Drug: BIBF 1120;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified November 2009

  • A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

    Condition:   Melanoma
    Interventions:   Drug: YM155;   Drug: Docetaxel
    Sponsor:   Astellas Pharma Inc
    Recruiting - verified November 2009

  • The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

    Condition:   Onychomycosis
    Interventions:   Drug: IDP-108;   Drug: Vehicle
    Sponsor:   Dow Pharmaceutical Sciences
    Not yet recruiting - verified November 2009

  • A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: methotrexate
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis

    Condition:   Onychomycosis
    Interventions:   Drug: IDP-108;   Drug: Vehicle
    Sponsor:   Dow Pharmaceutical Sciences
    Not yet recruiting - verified November 2009

  • Study of A3309 in Patients With Chronic Idiopathic Constipation

    Conditions:   Constipation;   Chronic Constipation
    Intervention:   Drug: A3309
    Sponsor:   Albireo
    Recruiting - verified November 2009

  • A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

    Condition:   Solid Tumors
    Intervention:   Drug: BGJ398
    Sponsor:   Novartis Pharmaceuticals
    Not yet recruiting - verified October 2009

  • Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

    Conditions:   Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

    Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
    Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
    Recruiting - verified November 2009

  • A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy

    Condition:   Pregnancy Prevention
    Intervention:   Drug: DR-103
    Sponsor:   Teva Women's Health
    Recruiting - verified October 2009

  • TAXUS Libertē Post Approval Study

    Condition:   Coronary Artery Disease
    Interventions:   Device: TAXUS Liberté Paclitaxel-Eluting Coronary Stent;   Drug: prasugrel;   Drug: placebo;   Drug: aspirin
    Sponsors:   Boston Scientific Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.
    Not yet recruiting - verified November 2009

  • The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis

    Condition:   Psoriasis
    Interventions:   Drug: Methotrexate and Etanercept;   Drug: Etanercept ONLY
    Sponsors:   Amgen;   Immunex Corporation
    Not yet recruiting - verified November 2009

  • Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

    Conditions:   Carcinoma, Hepatocellular;   Liver Diseases;   Neoplasms by Histologic Type;   Digestive System Neoplasms;   Carcinoma;   Liver Neoplasms;   Neoplasms;   Neoplasms by Site;   Digestive System Diseases;   Adenocarcinoma;   Neoplasms, Glandular and Epithelial
    Interventions:   Drug: ABT-869;   Drug: Sorafenib
    Sponsors:   Abbott;   Genentech
    Recruiting - verified November 2009

  • Safety and Efficacy of AIN457 in Behçet's Patients With Posterior or Panuveitis

    Condition:   Behcet Disease
    Interventions:   Biological: AIN457;   Biological: AIN457;   Biological: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified November 2009

  • Safety and Tolerability of TAK-491 Plus Chlorthalidone Compared to Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Essential Hypertension

    Condition:   Essential Hypertension
    Interventions:   Drug: TAK-491 and chlorthalidone;   Drug: Olmesartan medoxomil-hydrochlorothiazide
    Sponsor:   Takeda Global Research & Development Center, Inc.
    Recruiting - verified November 2009

  • Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth

    Conditions:   HIV Infections;   H1N1 Influenza Virus
    Intervention:   Biological: Influenza A (H1N1) 2009 monovalent vaccine
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Not yet recruiting - verified October 2009

  • Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

    Conditions:   HIV Infections;   H1N1 Influenza Virus
    Intervention:   Biological: Influenza A (H1N1) monovalent vaccine
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified October 2009

  • Localized Alveolar Ridge Augmentation With Space Maintenance Devices

    Condition:   Alveolar Bone Loss
    Intervention:   Device: INFUSE® Bone Graft
    Sponsors:   Medtronic Spinal and Biologics;   Averion International Corporation
    Recruiting - verified October 2009

  • Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

    Condition:   Castrate-Resistant Prostate Cancer
    Intervention:   Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
    Sponsor:   Celgene Corporation
    Recruiting - verified November 2009

  • A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds

    Condition:   Human Papillomavirus Infection
    Interventions:   Biological: V503;   Biological: Comparator: Menactra™ (Concomitant);   Biological: Comparator: Adacel™ (concomitant);   Biological: Comparator: Menactra™ (Non-Concomitant);   Biological: Comparator: Adacel™ (Non-concomitant)
    Sponsor:   Merck
    Recruiting - verified November 2009

  • Long Term Safety and Efficacy Trial of Budesonide Dipropionate - Hydroflouroalkane (BDP-HFA) 320 Mcg in Allergic Rhinitis

    Condition:   Rhinitis, Allergic, Perennial
    Interventions:   Drug: BDP;   Drug: Placebo
    Sponsor:   Teva Global Respiratory Research LLC
    Recruiting - verified October 2009

  • A Study of Advanced or Metastatic Non-small Cell Lung Cancer

    Condition:   Non Small Cell Lung Cancer
    Interventions:   Drug: LY2603618;   Drug: Pemetrexed
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • Carboplatin and Paclitaxel Combined With Cetuximab and/or Cixutumumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: cetuximab;   Biological: cixutumumab;   Drug: carboplatin;   Drug: paclitaxel
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

    Conditions:   Hepatitis;   Hepatitis C
    Interventions:   Drug: Filibuvir;   Drug: Filibuvir;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • RELIEF: Healthcase Utilization and Outcomes of FinESS Treatment in the Office

    Condition:   Rhinosinusitis
    Intervention:   Device: FinESS Sinus Treatment
    Sponsor:   Entellus Medical, Inc.
    Recruiting - verified November 2009

  • A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

    Condition:   Neoplasms
    Interventions:   Drug: R1507;   Drug: RAD001
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Dapagliflozin DPPIV Inhibitor add-on Study

    Condition:   Type 2 Diabetes
    Interventions:   Drug: Dapagliflozin;   Drug: Placebo
    Sponsors:   AstraZeneca;   Bristol-Myers Squibb
    Recruiting - verified November 2009

  • The Dual Antiplatelet Therapy Study (DAPT Study)

    Condition:   Coronary Artery Disease
    Interventions:   Drug: Placebo & Aspirin;   Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
    Sponsors:   Harvard Clinical Research Institute;   Abbott;   Boston Scientific Corporation;   Bristol-Myers Squibb;   Sanofi-Synthelabo;   Cordis Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.;   Medtronic
    Recruiting - verified November 2009

  • Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne

    Condition:   Severe Nodular Acne
    Intervention:   Drug: CIP-Isotretinoin and Isotretinoin
    Sponsor:   Cipher Pharmaceuticals Inc.
    Recruiting - verified November 2009

  • Efficacy and Safety Study of NBI-56418 Na in Subjects With Endometriosis

    Conditions:   Endometriosis;   Pain
    Interventions:   Drug: NBI-56418;   Drug: Placebo
    Sponsor:   Neurocrine Biosciences
    Recruiting - verified November 2009

  • Safety and Efficacy of F2695 SR in Major Depressive Disorder

    Condition:   Major Depressive Disorder
    Interventions:   Drug: F2695 SR;   Drug: F2695 SR;   Drug: F2695 SR;   Drug: Placebo
    Sponsor:   Forest Laboratories
    Recruiting - verified November 2009

  • A Study in Patients With Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Biological: LY2439821;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • Genotropin Study Assessing Use of Injection Pen

    Conditions:   Growthe Hormone Deficiency;   Idiopathic Short Stature
    Intervention:   Device: New Genotropin Pen
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Depression Outcomes Study of Exercise

    Condition:   Major Depressive Disorder (MDD)
    Interventions:   Other: Public Health Dose of Exercise (PHD);   Other: Low Dose Exercise (LD)
    Sponsors:   Klein Buendel, Inc.;   University of Colorado at Denver and Health Sciences Center
    Recruiting - verified August 2009

  • A Study of RO5190591 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

    Condition:   Hepatitis C, Chronic
    Interventions:   Drug: RO5190591;   Drug: RO5190591;   Drug: RO5190591;   Drug: RO5190591;   Drug: Placebo;   Drug: Placebo;   Drug: Pegasys;   Drug: Copegus
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • A Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult and Adolescent Hospitalized Subjects With Confirmed or Suspected Influenza Infection

    Conditions:   Seasonal Influenza;   Cough;   Sore Throat;   Nasal Congestion;   Myalgia;   Headache;   Feverishness;   Fatigue
    Interventions:   Drug: Peramivir;   Drug: Peramivir
    Sponsors:   BioCryst Pharmaceuticals;   Department of Health and Human Services
    Recruiting - verified November 2009

  • Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

    Condition:   Subjective Tinnitus
    Interventions:   Drug: Neramexane mesylate;   Drug: Placebo
    Sponsor:   Merz Pharmaceuticals GmbH
    Recruiting - verified November 2009

  • COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

    Condition:   Myelofibrosis
    Interventions:   Drug: INCB018424;   Drug: Placebo
    Sponsor:   Incyte Corporation
    Recruiting - verified November 2009

  • Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II or Stage III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

    Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Trinity Evolution in Anterior Cervical Disectomy and Fusion (ACDF)

    Condition:   Degenerative Disc Disease
    Intervention:  
    Sponsor:   Orthofix, Inc.
    Recruiting - verified November 2009

  • A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

    Condition:   Malignant Melanoma
    Intervention:   Drug: RO5185426
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin

    Condition:   Diabetes Mellitus, Type II
    Interventions:   Drug: Dutogliptin;   Drug: Placebo
    Sponsors:   Forest Laboratories;   Phenomix
    Recruiting - verified October 2009

  • Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

    Condition:   Benign Prostatic Hyperplasia (BPH)
    Interventions:   Drug: NX-1207;   Drug: Placebo
    Sponsor:   Nymox Corporation
    Recruiting - verified October 2009

  • Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

    Conditions:   Kidney Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes

    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: liraglutide;   Drug: placebo;   Drug: liraglutide;   Drug: placebo
    Sponsor:   Novo Nordisk
    Recruiting - verified November 2009

  • Study of ITCA 650 in Subjects With Type 2 Diabetes Mellitus

    Condition:   Type 2 Diabetes
    Interventions:   Drug: ITCA 650;   Drug: Exenatide
    Sponsor:   Intarcia Therapeutics
    Recruiting - verified November 2009

    • Menu
    Find Paid Clinical Trials